Phaseline

Companies › Vico Therapeutics B. V.

Vico Therapeutics B. V.: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Neurology; next expected readout Apr 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
VO659
Antisense oligonucleotide targeting CAG repeats
CAGPhase 1Spinocerebellar Ataxia Type 1Apr 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05822908VO659Phase 1Spinocerebellar Ataxia Type 1NeurologyApr 2028

Targets

CAG (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.